Tianjin Medical Journal ›› 2025, Vol. 53 ›› Issue (2): 135-140.doi: 10.11958/20241271
• Clinical Research • Previous Articles Next Articles
WEI Chanjuan(), XIA Xiaoshuang, FENG Wenjun, LI Xin(
)
Received:
2024-09-09
Revised:
2024-11-13
Published:
2025-02-15
Online:
2025-02-26
Contact:
△ E-mail:WEI Chanjuan, XIA Xiaoshuang, FENG Wenjun, LI Xin. The predictive value of neutrophil-to-lymphocyte ratio for poor prognosis in patients with acute ischemic stroke undergoing intravenous thrombolysis[J]. Tianjin Medical Journal, 2025, 53(2): 135-140.
CLC Number:
组别 | n | 男性 | 年龄/ 岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂血症 | 冠心病 | 心房颤动 | 既往卒中或TIA | SBP/ mmHg | DBP/ mmHg | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
预后良好组 | 135 | 93(68.9) | 65.8±11.5 | 54(40.0) | 45(33.3) | 85(63.0) | 26(19.3) | 63(46.7) | 30(22.2) | 24(17.8) | 32(23.7) | 149.7±18.7 | 84.8±13.9 | ||||||||||
预后不良组 | 86 | 45(51.3) | 71.3±12.3 | 37(43.0) | 21(24.4) | 71(82.6) | 31(36.0) | 49(57.0) | 41(47.7) | 26(30.2) | 28(32.6) | 153.9±19.1 | 84.4±16.2 | ||||||||||
χ2或t | 6.146* | 3.405** | 0.198 | 1.993 | 9.716** | 7.735** | 2.234 | 15.607** | 4.655** | 2.082 | 1.608 | 0.195 | |||||||||||
组别 | WBC/ (×109/L) | NEU/ (×109/L) | LYM/ (×109/L) | NLR | LDL-C/ (mmol/L) | 随机血糖/(mmol/L) | HCY/ (μmol/L) | OST/ min | OTT/ min | NIHSS 评分/分 | |||||||||||||
预后良好组 | 7.6±2.3 | 4.0(3.4,5.3) | 2.3(1.7,2.8) | 1.8(1.3,2.6) | 3.1±0.1 | 6.4(5.7,7.7) | 12.9(10.7,16.1) | 86(55,125) | 130(100,168) | 5(3,11) | |||||||||||||
预后不良组 | 8.0±2.3 | 5.0(4.1,7.0) | 1.6(1.2,2.2) | 3.3(2.1,5.1) | 3.2±0.1 | 7.0(5.9,9.8) | 14.3(11.1,19.8) | 75(45,125) | 125(95,175) | 15(10,19) | |||||||||||||
t或Z | 1.349 | 4.159** | 5.560** | 6.210** | 0.770 | 2.272** | 1.741 | 0.872 | 0.053 | 7.886** |
Tab.1 Comparison of baseline characteristics of AIS patients between different prognostic groups
组别 | n | 男性 | 年龄/ 岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂血症 | 冠心病 | 心房颤动 | 既往卒中或TIA | SBP/ mmHg | DBP/ mmHg | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
预后良好组 | 135 | 93(68.9) | 65.8±11.5 | 54(40.0) | 45(33.3) | 85(63.0) | 26(19.3) | 63(46.7) | 30(22.2) | 24(17.8) | 32(23.7) | 149.7±18.7 | 84.8±13.9 | ||||||||||
预后不良组 | 86 | 45(51.3) | 71.3±12.3 | 37(43.0) | 21(24.4) | 71(82.6) | 31(36.0) | 49(57.0) | 41(47.7) | 26(30.2) | 28(32.6) | 153.9±19.1 | 84.4±16.2 | ||||||||||
χ2或t | 6.146* | 3.405** | 0.198 | 1.993 | 9.716** | 7.735** | 2.234 | 15.607** | 4.655** | 2.082 | 1.608 | 0.195 | |||||||||||
组别 | WBC/ (×109/L) | NEU/ (×109/L) | LYM/ (×109/L) | NLR | LDL-C/ (mmol/L) | 随机血糖/(mmol/L) | HCY/ (μmol/L) | OST/ min | OTT/ min | NIHSS 评分/分 | |||||||||||||
预后良好组 | 7.6±2.3 | 4.0(3.4,5.3) | 2.3(1.7,2.8) | 1.8(1.3,2.6) | 3.1±0.1 | 6.4(5.7,7.7) | 12.9(10.7,16.1) | 86(55,125) | 130(100,168) | 5(3,11) | |||||||||||||
预后不良组 | 8.0±2.3 | 5.0(4.1,7.0) | 1.6(1.2,2.2) | 3.3(2.1,5.1) | 3.2±0.1 | 7.0(5.9,9.8) | 14.3(11.1,19.8) | 75(45,125) | 125(95,175) | 15(10,19) | |||||||||||||
t或Z | 1.349 | 4.159** | 5.560** | 6.210** | 0.770 | 2.272** | 1.741 | 0.872 | 0.053 | 7.886** |
变量 | β | SE | Wald χ2 | P | OR(95%CI) |
---|---|---|---|---|---|
性别 | 0.863 | 0.384 | 5.040 | 0.025 | 2.370(1.116~5.036) |
高血压 | 0.959 | 0.462 | 4.321 | 0.038 | 2.610(1.056~6.449) |
NLR | 0.677 | 0.133 | 25.864 | <0.001 | 1.968(1.516~2.555) |
基线NIHSS评分 | 0.211 | 0.033 | 40.813 | <0.001 | 1.235(1.158~1.318) |
常数项 | -6.693 | 0.990 | 45.712 | <0.001 | 0.001 |
Tab.2 Multivariable Logistic regression analysis of 3-month poor prognosis in AIS patients
变量 | β | SE | Wald χ2 | P | OR(95%CI) |
---|---|---|---|---|---|
性别 | 0.863 | 0.384 | 5.040 | 0.025 | 2.370(1.116~5.036) |
高血压 | 0.959 | 0.462 | 4.321 | 0.038 | 2.610(1.056~6.449) |
NLR | 0.677 | 0.133 | 25.864 | <0.001 | 1.968(1.516~2.555) |
基线NIHSS评分 | 0.211 | 0.033 | 40.813 | <0.001 | 1.235(1.158~1.318) |
常数项 | -6.693 | 0.990 | 45.712 | <0.001 | 0.001 |
组别 | n | 男性 | 年龄/岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂血症 | 冠心病 | 心房颤动 | 既往卒中 或TIA | SBP/ mmHg | DBP/ mmHg | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
非死亡组 | 202 | 132(65.3) | 67.4±11.9 | 85(42.1) | 62(30.7) | 138(68.3) | 47(23.3) | 99(49.0) | 58(28.7) | 44(21.8) | 49(24.3) | 150.8±18.8 | 85.0±14.6 | ||||||||||
死亡组 | 19 | 6(31.6) | 73.8±13.2 | 6(31.6) | 4(21.1) | 18(94.7) | 10(52.6) | 13(68.4) | 13(68.4) | 6(31.6) | 11(57.9) | 157.6±19.9 | 81.3±17.0 | ||||||||||
χ2或t | 8.444** | 2.242** | 0.791 | 0.771 | 5.839* | 6.365* | 2.618 | 12.558** | 0.491 | 9.935** | 1.520 | 1.035 | |||||||||||
组别 | WBC/ (×109/L) | NEU/ (×109/L) | LYM/ (×109/L) | NLR | LDL-C/ (mmol/L) | 随机血糖/ (mmol/L) | HCY/ (μmol/L) | OST/ min | OTT/ min | NIHSS 评分/分 | |||||||||||||
非死亡组 | 7.7±2.3 | 4.3(3.5,5.8) | 2.1(1.5,2.7) | 2.1(1.4,3.3) | 3.1±0.9 | 6.6(5.7,8.1) | 13.2(10.8,17.5) | 85(50,125) | 125(95,170) | 7(4,14) | |||||||||||||
死亡组 | 8.1±2.0 | 5.7(4.2,7.4) | 1.5(1.0,2.0) | 3.7(2.2,6.0) | 3.4±1.3 | 7.9(6.4,12.8) | 12.5(10.8,16.6) | 71(50,115) | 130(110,180) | 18(15,20) | |||||||||||||
t或Z | 0.715 | 2.233* | 2.991** | 3.423** | 1.204 | 2.659** | 0.186 | 0.800 | 1.109 | 4.835** |
Tab.3 Comparison of baseline characteristics in AIS patients between the mortality group and the non-mortality group
组别 | n | 男性 | 年龄/岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂血症 | 冠心病 | 心房颤动 | 既往卒中 或TIA | SBP/ mmHg | DBP/ mmHg | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
非死亡组 | 202 | 132(65.3) | 67.4±11.9 | 85(42.1) | 62(30.7) | 138(68.3) | 47(23.3) | 99(49.0) | 58(28.7) | 44(21.8) | 49(24.3) | 150.8±18.8 | 85.0±14.6 | ||||||||||
死亡组 | 19 | 6(31.6) | 73.8±13.2 | 6(31.6) | 4(21.1) | 18(94.7) | 10(52.6) | 13(68.4) | 13(68.4) | 6(31.6) | 11(57.9) | 157.6±19.9 | 81.3±17.0 | ||||||||||
χ2或t | 8.444** | 2.242** | 0.791 | 0.771 | 5.839* | 6.365* | 2.618 | 12.558** | 0.491 | 9.935** | 1.520 | 1.035 | |||||||||||
组别 | WBC/ (×109/L) | NEU/ (×109/L) | LYM/ (×109/L) | NLR | LDL-C/ (mmol/L) | 随机血糖/ (mmol/L) | HCY/ (μmol/L) | OST/ min | OTT/ min | NIHSS 评分/分 | |||||||||||||
非死亡组 | 7.7±2.3 | 4.3(3.5,5.8) | 2.1(1.5,2.7) | 2.1(1.4,3.3) | 3.1±0.9 | 6.6(5.7,8.1) | 13.2(10.8,17.5) | 85(50,125) | 125(95,170) | 7(4,14) | |||||||||||||
死亡组 | 8.1±2.0 | 5.7(4.2,7.4) | 1.5(1.0,2.0) | 3.7(2.2,6.0) | 3.4±1.3 | 7.9(6.4,12.8) | 12.5(10.8,16.6) | 71(50,115) | 130(110,180) | 18(15,20) | |||||||||||||
t或Z | 0.715 | 2.233* | 2.991** | 3.423** | 1.204 | 2.659** | 0.186 | 0.800 | 1.109 | 4.835** |
变量 | β | SE | Wald χ2 | P | OR(95%CI) |
---|---|---|---|---|---|
性别 | 2.080 | 0.698 | 8.890 | 0.003 | 8.005(2.040~31.420) |
卒中或TIA | 1.475 | 0.629 | 5.496 | 0.019 | 4.732(1.274~15.008) |
NLR | 0.275 | 0.127 | 4.729 | 0.030 | 1.317(1.028~1.688) |
随机血糖 | 0.197 | 0.074 | 7.008 | 0.008 | 1.218(1.052~1.408) |
NIHSS评分 | 0.188 | 0.051 | 13.684 | <0.001 | 1.207(1.092~1.333) |
常数项 | -11.429 | 2.124 | 28.959 | <0.001 | 0.000 |
Tab.4 Multivariable Logistic regression analysis of 3-month mortality in AIS patients
变量 | β | SE | Wald χ2 | P | OR(95%CI) |
---|---|---|---|---|---|
性别 | 2.080 | 0.698 | 8.890 | 0.003 | 8.005(2.040~31.420) |
卒中或TIA | 1.475 | 0.629 | 5.496 | 0.019 | 4.732(1.274~15.008) |
NLR | 0.275 | 0.127 | 4.729 | 0.030 | 1.317(1.028~1.688) |
随机血糖 | 0.197 | 0.074 | 7.008 | 0.008 | 1.218(1.052~1.408) |
NIHSS评分 | 0.188 | 0.051 | 13.684 | <0.001 | 1.207(1.092~1.333) |
常数项 | -11.429 | 2.124 | 28.959 | <0.001 | 0.000 |
组别 | n | 男性 | 年龄/ 岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂 血症 | 冠心病 | 心房 颤动 | 既往卒中 或TIA | SBP/ mmHg | DBP/ mmHg | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
非END组 | 163 | 108(66.3) | 66.9±12.0 | 63(38.7) | 50(30.7) | 107(65.6) | 35(21.5) | 78(47.9) | 41(25.2) | 31(19.0) | 39(23.9) | 150.3±18.4 | 84.8±14.5 | |||||||||||
END组 | 58 | 30(51.7) | 71.0±12.0 | 28(48.3) | 16(27.6) | 49(84.5) | 22(37.9) | 34(58.6) | 30(51.7) | 19(32.8) | 21(36.2) | 154.2±20.1 | 84.3±15.7 | |||||||||||
χ2或t | 3.853 | 2.272** | 1.636 | 0.195 | 7.313** | 6.054** | 1.984 | 13.851** | 4.613** | 3.262 | 1.337 | 0.238 | ||||||||||||
组别 | WBC/ (×109/L) | NEU/ (×109/L) | LYM/ (×109/L) | NLR | LDL-C/ (mmol/L) | 随机血糖/ (mmol/L) | HCY/ (μmol/L) | OST/ min | OTT/ min | NIHSS 评分/分 | ||||||||||||||
非END组 | 7.5±2.1 | 4.2(3.4,5.5) | 2.1(1.6,2.7) | 2.0(1.3,2.9) | 3.1±1.0 | 6.5(5.7,7.9) | 12.7(10.7,16.4) | 85(53,125) | 125(95,170) | 7(3,14) | ||||||||||||||
END组 | 8.4±2.6 | 5.1(4.1,7.3) | 1.6(1.2,2.3) | 3.3(2.1,5.1) | 3.2±1.0 | 7.1(5.9,9.9) | 15.1(11.3,20.5) | 82(47,125) | 130(103,176) | 14(7,18) | ||||||||||||||
t或Z | 2.506** | 3.963** | 3.690** | 5.206** | 0.610 | 1.875 | 2.280** | 0.359 | 0.931 | 4.167** |
Tab.5 Comparison of baseline characteristics in AIS patients between the END group and the non-END group
组别 | n | 男性 | 年龄/ 岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂 血症 | 冠心病 | 心房 颤动 | 既往卒中 或TIA | SBP/ mmHg | DBP/ mmHg | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
非END组 | 163 | 108(66.3) | 66.9±12.0 | 63(38.7) | 50(30.7) | 107(65.6) | 35(21.5) | 78(47.9) | 41(25.2) | 31(19.0) | 39(23.9) | 150.3±18.4 | 84.8±14.5 | |||||||||||
END组 | 58 | 30(51.7) | 71.0±12.0 | 28(48.3) | 16(27.6) | 49(84.5) | 22(37.9) | 34(58.6) | 30(51.7) | 19(32.8) | 21(36.2) | 154.2±20.1 | 84.3±15.7 | |||||||||||
χ2或t | 3.853 | 2.272** | 1.636 | 0.195 | 7.313** | 6.054** | 1.984 | 13.851** | 4.613** | 3.262 | 1.337 | 0.238 | ||||||||||||
组别 | WBC/ (×109/L) | NEU/ (×109/L) | LYM/ (×109/L) | NLR | LDL-C/ (mmol/L) | 随机血糖/ (mmol/L) | HCY/ (μmol/L) | OST/ min | OTT/ min | NIHSS 评分/分 | ||||||||||||||
非END组 | 7.5±2.1 | 4.2(3.4,5.5) | 2.1(1.6,2.7) | 2.0(1.3,2.9) | 3.1±1.0 | 6.5(5.7,7.9) | 12.7(10.7,16.4) | 85(53,125) | 125(95,170) | 7(3,14) | ||||||||||||||
END组 | 8.4±2.6 | 5.1(4.1,7.3) | 1.6(1.2,2.3) | 3.3(2.1,5.1) | 3.2±1.0 | 7.1(5.9,9.9) | 15.1(11.3,20.5) | 82(47,125) | 130(103,176) | 14(7,18) | ||||||||||||||
t或Z | 2.506** | 3.963** | 3.690** | 5.206** | 0.610 | 1.875 | 2.280** | 0.359 | 0.931 | 4.167** |
变量 | β | SE | Wald χ2 | P | OR(95%CI) |
---|---|---|---|---|---|
高血压 | 0.994 | 0.443 | 5.028 | 0.025 | 2.703(1.133~6.444) |
NLR | 0.350 | 0.095 | 13.746 | <0.001 | 1.420(1.180~1.709) |
HCY | 0.038 | 0.018 | 4.495 | 0.034 | 1.038(1.003~1.075) |
NIHSS评分 | 0.062 | 0.025 | 5.922 | 0.015 | 1.064(1.012~1.118) |
常数项 | -6.156 | 1.341 | 21.087 | <0.001 | 0.002 |
Tab.6 Multivariable Logistic regression analysis of END in AIS patients
变量 | β | SE | Wald χ2 | P | OR(95%CI) |
---|---|---|---|---|---|
高血压 | 0.994 | 0.443 | 5.028 | 0.025 | 2.703(1.133~6.444) |
NLR | 0.350 | 0.095 | 13.746 | <0.001 | 1.420(1.180~1.709) |
HCY | 0.038 | 0.018 | 4.495 | 0.034 | 1.038(1.003~1.075) |
NIHSS评分 | 0.062 | 0.025 | 5.922 | 0.015 | 1.064(1.012~1.118) |
常数项 | -6.156 | 1.341 | 21.087 | <0.001 | 0.002 |
临床结局 | AUC(95%CI) | P | 截断值 | 敏感度/ % | 特异度/ % | 约登 指数 |
---|---|---|---|---|---|---|
预后不良 | 0.748(0.679~0.817) | <0.001 | 2.63 | 67.4 | 77.8 | 0.452 |
死亡 | 0.738(0.622~0.853) | 0.001 | 3.12 | 68.4 | 73.8 | 0.422 |
END | 0.730(0.656~0.804) | <0.001 | 2.63 | 67.2 | 69.9 | 0.371 |
SICH | 0.565(0.303~0.826) | 0.620 | - | - | - | - |
Tab.7 Predictive effect of baseline NLR on clinical outcomes
临床结局 | AUC(95%CI) | P | 截断值 | 敏感度/ % | 特异度/ % | 约登 指数 |
---|---|---|---|---|---|---|
预后不良 | 0.748(0.679~0.817) | <0.001 | 2.63 | 67.4 | 77.8 | 0.452 |
死亡 | 0.738(0.622~0.853) | 0.001 | 3.12 | 68.4 | 73.8 | 0.422 |
END | 0.730(0.656~0.804) | <0.001 | 2.63 | 67.2 | 69.9 | 0.371 |
SICH | 0.565(0.303~0.826) | 0.620 | - | - | - | - |
组别 | n | 男性 | 年龄/岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂 血症 | 冠心病 | 心房 颤动 | 既往卒中 或TIA | SBP/ mmHg | DBP/ mmHg | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
低NLR组 | 132 | 85(64.4) | 67.22±12.09 | 54(40.9) | 42(31.8) | 85(64.4) | 28(21.2) | 61(46.2) | 34(25.8) | 30(22.7) | 31(23.5) | 150.9±18.7 | 85.4±15.5 | |||||||||
高NLR组 | 89 | 53(60.0) | 69.02±12.10 | 37(41.6) | 24(27.0) | 71(79.8) | 29(32.6) | 51(57.3) | 37(41.6) | 20(22.5) | 29(32.6) | 152.1±19.3 | 83.6±13.7 | |||||||||
χ2或t | 0.532 | 1.087 | 0.010 | 0.597 | 6.058** | 3.592 | 2.616 | 6.098* | 0.002 | 2.225 | 0.469 | 0.918 | ||||||||||
组别 | NIHSS 评分/分 | 随机血糖/ (mmol/L) | LDL-C/ (mmol/L) | HCY/ (μmol/L) | SICH | END | 3个月 预后不良 | 3个月 死亡 | ||||||||||||||
低NLR组 | 7(3,14) | 7.2±2.8 | 3.1±1.0 | 13.2(10.7,18.0) | 2(1.5) | 19(14.4) | 28(21.2) | 5(3.8) | ||||||||||||||
高NLR组 | 10(6,18) | 8.5±3.5 | 3.1±0.9 | 12.7(10.9,16.7) | 3(3.4) | 39(43.8) | 58(65.2) | 14(15.7) | ||||||||||||||
Z、t或χ2 | 2.872** | 2.844** | 0.324 | 0.267 | 0.654 | 23.780** | 43.208** | 9.648** |
Tab.8 Comparison of baseline characteristics and clinical outcomes in AIS patients between the high NLR group and the low NLR group
组别 | n | 男性 | 年龄/岁 | 吸烟 | 饮酒 | 高血压 | 糖尿病 | 高脂 血症 | 冠心病 | 心房 颤动 | 既往卒中 或TIA | SBP/ mmHg | DBP/ mmHg | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
低NLR组 | 132 | 85(64.4) | 67.22±12.09 | 54(40.9) | 42(31.8) | 85(64.4) | 28(21.2) | 61(46.2) | 34(25.8) | 30(22.7) | 31(23.5) | 150.9±18.7 | 85.4±15.5 | |||||||||
高NLR组 | 89 | 53(60.0) | 69.02±12.10 | 37(41.6) | 24(27.0) | 71(79.8) | 29(32.6) | 51(57.3) | 37(41.6) | 20(22.5) | 29(32.6) | 152.1±19.3 | 83.6±13.7 | |||||||||
χ2或t | 0.532 | 1.087 | 0.010 | 0.597 | 6.058** | 3.592 | 2.616 | 6.098* | 0.002 | 2.225 | 0.469 | 0.918 | ||||||||||
组别 | NIHSS 评分/分 | 随机血糖/ (mmol/L) | LDL-C/ (mmol/L) | HCY/ (μmol/L) | SICH | END | 3个月 预后不良 | 3个月 死亡 | ||||||||||||||
低NLR组 | 7(3,14) | 7.2±2.8 | 3.1±1.0 | 13.2(10.7,18.0) | 2(1.5) | 19(14.4) | 28(21.2) | 5(3.8) | ||||||||||||||
高NLR组 | 10(6,18) | 8.5±3.5 | 3.1±0.9 | 12.7(10.9,16.7) | 3(3.4) | 39(43.8) | 58(65.2) | 14(15.7) | ||||||||||||||
Z、t或χ2 | 2.872** | 2.844** | 0.324 | 0.267 | 0.654 | 23.780** | 43.208** | 9.648** |
[1] | WANG L Y, HAO M J, WU N, et al. Comprehensive review of tenecteplase for thrombolysis in acute ischemic stroke[J]. J Am Heart Assoc, 2024, 13(9):e031692. doi:10.1161/JAHA.123.031692. |
[2] | GARCÍA-ESCOBAR A, VERA-VERA S, TÉBAR-MÁRQUEZ D, et al. Neutrophil-to-lymphocyte ratio an inflammatory biomarker,and prognostic marker in heart failure,cardiovascular disease and chronic inflammatory diseases:New insights for a potential predictor of anti-cytokine therapy responsiveness[J]. Microvasc Res, 2023, 150:104598. doi:10.1016/j.mvr.2023.104598. |
[3] | WANG C B, ZHANG Q, JI M W, et al. Prognostic value of the neutrophil-to-lymphocyte ratio in acute ischemic stroke patients treated with intravenous thrombolysis:a systematic review and meta-analysis[J]. BMC Neurol, 2021, 21(1):191. doi:10.1186/s12883-021-02222-8. |
[4] | ÖREN O, HAKI C, KAYA H, et al. Predictive value of admission neutrophil/lymphocyte ratio in symptomatic intracranial hemorrhage after stroke thrombolysis[J]. Neurol Sci, 2022, 43(1):435-440. doi:10.1007/s10072-021-05326-8. |
[5] | 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682. |
Chinese Society of Neurology,Chinese Medical Association,Stroke Study Group,Chinese Society of Neurology,Chinese Medical Association. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9):666-682. doi:10.3760/cma.j.issn.1006-7876.2018.09.004. | |
[6] | MISTRY E A, YEATTS S D, KHATRI P, et al. National institutes of health stroke scale as an outcome in stroke research:value of ANCOVA over analyzing change from baseline[J]. Stroke, 2022, 53(4):e150-e155. doi:10.1161/STROKEAHA.121.034859. |
[7] | KOBEISSI H, GHOZY S, ADUSUMILLI G, et al. Endovascular therapy for stroke presenting beyond 24 hours:a systematic review and meta-analysis[J]. JAMA Netw Open, 2023, 6(5):e2311768. doi:10.1001/jamanetworkopen.2023.11768. |
[8] | HACKE W, KASTE M, FIESCHI C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators[J]. Lancet, 1998, 352(9136):1245-1251. doi:10.1016/s0140-6736(98)08020-9. |
[9] | TIAN T, WANG L J, XU J L, et al. Prediction of early neurological deterioration in acute ischemic stroke patients treated with intravenous thrombolysis[J]. J Cereb Blood Flow Metab, 2023, 43(12):2049-2059. doi:10.1177/0271678X231200117. |
[10] | CHEN Q X, WU M M, TANG Q, et al. Age-related alterations in immune function and inflammation:focus on ischemic stroke[J]. Aging Dis, 2024, 15(3):1046-1074. doi:10.14336/AD.2023.0721-1. |
[11] | MA G Q, PAN Z R, KONF L L, et al. Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis:Potential mechanisms,targets,therapeutic drugs and biomarkers[J]. Int Immunopharmacol, 2021, 90:107216. doi:10.1016/j.intimp.2020.107216. |
[12] | CEULEMANS A G, ZGAVC T, KOOIJMAN R, et al. The dual role of the neuroinflammatory response after ischemic stroke:modulatory effects of hypothermia[J]. J Neuroinflammation, 2010, 7:74. doi:10.1186/1742-2094-7-74. |
[13] | LUO Y, XIA L X, LI Z L, et al. Early neutrophil-to-lymphocyte ratio is a prognostic marker in acute minor stroke or transient ischemic attack[J]. Acta Neurol Belg, 2021, 121(6):1415-1421. doi:10.1007/s13760-020-01289-3. |
[14] | 胡明哲, 陈香岩, 吴光亮, 等. 中性粒细胞淋巴细胞比值、淋巴细胞单核细胞比值与症状性颅内动脉粥样硬化性狭窄的关系[J]. 天津医药, 2022, 50(5):493-497. |
HU M Z, CHEN X Y, WU G L, et al. Research on the correlation between neutrophil lymphocyte ratio,lymphocyte monocyte ratio and symptomatic intracranial atherosclerotic stenosis[J]. Tianjin Med J, 2022, 50(5):493-497. doi:10.11958/20212251. | |
[15] | 陈炎, 王盛磊, 董斌, 等. 基线中性粒细胞和中性粒细胞与淋巴细胞比值与脑梗死溶栓患者预后的研究[J]. 中华老年心脑血管病杂志, 2023, 25(2):202-204. |
CHEN Y, WANG S L, DONG B, et al. Baseline neutrophils and neutrophil-to-lymphocyte ratio and prognosis in patients with thrombolysis for cerebral infarction[J]. Chinese Journal of Geriatric Cardiovascular Disease, 2023, 25(2):202-204. doi:10.3969/j.issn.1009-0126.2023.02.022. | |
[16] | WANG C T, ZHOU M L, KANG T T, et al. The prognostic value of combined uric acid and neutrophil-to-lymphocyte ratio in acute ischemic stroke patients treated with intravenous thrombolysis[J]. BMC Neurol, 2024, 24(1):183. doi:10.1186/s12883-024-03628-w. |
[17] | LIU Y L, WU Z Q, QU J F, et al. High neutrophil-to-lymphocyte ratio is a predictor of poor short-term outcome in patients with mild acute ischemic stroke receiving intravenous thrombolysis[J]. Brain Behav, 2020, 10(12):e01857. doi:10.1002/brb3.1857. |
[18] | YING A, CHENG Y, LIN Y, et al. Dynamic increase in neutrophil levels predicts parenchymal hemorrhage and function outcome of ischemic stroke with r-tPA thrombolysis[J]. Neurol Sci, 2020, 41(8):2215-2223. doi:10.1007/s10072-020-04324-6. |
[19] | QIAN K, HU J, WANG C Y, et al. Dynamic change of neutrophil-to-lymphocyte ratio and its predictive value of prognosis in acute ischemic stroke[J]. Brain Behav, 2024, 14(7):e3616. doi:10.1002/brb3.3616. |
[20] | MALHOTRA K, GOYAL N, CHANG J J, et al. Differential leukocyte counts on admission predict outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis[J]. Eur J Neurol, 2018, 25(12):1417-1424. doi:10.1111/ene.13741. |
[21] | GONG P, XIE Y, JIANG T, et al. Neutrophil-lymphocyte ratio predicts post-thrombolysis early neurological deterioration in acute ischemic stroke patients[J]. Brain Behav, 2019, 9(10):e01426. doi:10.1002/brb3.1426. |
[22] | GONG P, LIU Y, GONG Y, et al. The association of neutrophil to lymphocyte ratio,platelet to lymphocyte ratio,and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke[J]. J Neuroinflammation, 2021, 18(1):51. doi:10.1186/s12974-021-02090-6. |
[23] | MA Y, XU D Y, LIU Q, et al. Nomogram prediction model for the risk of intracranial hemorrhagic transformation after intravenous thrombolysis in patients with acute ischemic stroke[J]. Front Neurol, 2024, 7(15):1361035. doi:10.3389/fneur.2024.1361035. |
[24] | XIE X H, YANG J, REN L J, et al. Nomogram to predict symptomatic intracranial hemorrhage after intravenous thrombolysis in acute ischemic stroke in asian population[J]. Curr Neurovasc Res, 2021, 18(5):543-551. doi:10.2174/1567202619666211223150907. |
[25] | WENG Z A, HUANG X X, DENG D, et al. A new nomogram for predicting the risk of intracranial hemorrhage in acute ischemic stroke patients after intravenous thrombolysis[J]. Front Neurol, 2022, 13:774654. doi:10.3389/fneur.2022.774654. |
[26] | LIU Y L, LU J K, YIN H P, et al. High neutrophil-to-lymphocyte ratio predicts hemorrhagic transformation in acute ischemic stroke patients treated with intravenous thrombolysis[J]. Int J Hypertens, 2020, 2020:5980261. doi:10.1155/2020/5980261. |
[27] | GUO Z, YU S, XIAO L, et al. Dynamic change of neutrophil to lymphocyte ratio and hemorrhagic transformation after thrombolysis in stroke[J]. J Neuroinflammation, 2016, 13(1):199. doi: 10.1186/s12974-016-0680-x. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||